{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T16:29:52Z","timestamp":1774974592114,"version":"3.50.1"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,15]]},"DOI":"10.2146\/ajhp140276","type":"journal-article","created":{"date-parts":[[2015,1,28]],"date-time":"2015-01-28T18:19:20Z","timestamp":1422469160000},"page":"301-307","source":"Crossref","is-referenced-by-count":14,"title":["Cost-utility analysis of botulinum toxin type A products for the treatment of cervical dystonia"],"prefix":"10.1093","volume":"72","author":[{"given":"Rashid","family":"Kazerooni","sequence":"first","affiliation":[{"name":"Veterans Affairs San Diego Healthcare System, San Diego, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Broadhead","sequence":"additional","affiliation":[{"name":"Sharp HealthCare, San Diego"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041008221806200_b1-0720301","first-page":"332","volume-title":"Movement disorders 2","author":"Fahn","year":"1987"},{"key":"key\n\t\t\t\t2019041008221806200_b2-0720301","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/mds.870060206","article-title":"Idiopathic cervical dystonia: clinical characteristics","volume":"6","author":"Chan","year":"1991","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b3-0720301","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","article-title":"Cervical dystonia: clinical findings and associated movement disorders","volume":"41","author":"Jankovic","year":"1991","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041008221806200_b4-0720301","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0304-3959(96)03296-4","article-title":"Pain in spasmodic torticollis","volume":"69","author":"Kutvonen","year":"1997","journal-title":"Pain"},{"key":"key\n\t\t\t\t2019041008221806200_b5-0720301","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/1531-8257(199911)14:6<1043::AID-MDS1026>3.0.CO;2-3","article-title":"Painful cervical dystonia: clinical features and response to treatment with botulinum toxin","volume":"14","author":"Tarsy","year":"1999","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b6-0720301","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/0303-8467(94)90072-8","article-title":"Idiopathic spasmodic torticollis: a survey of clinical syndromes and patients\u2019 experiences","volume":"96","author":"Van Herwaarden","year":"1994","journal-title":"Clin Neurol Neurosurg"},{"key":"key\n\t\t\t\t2019041008221806200_b7-0720301","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","article-title":"Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia","volume":"71","author":"Hilker","year":"2001","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t2019041008221806200_b8-0720301","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/mds.10127","article-title":"Impact of cervical dystonia on quality of life","volume":"17","author":"Camfield","year":"2002","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b9-0720301","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/mds.870030302","article-title":"Epidemiology of focal and generalized dystonia in Rochester, Minnesota","volume":"3","author":"Nutt","year":"1988","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b10-0720301","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","article-title":"Prevalence of cervical dystonia and spasmodic torticollis in the United States general population","volume":"13","author":"Jankovic","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b11-0720301","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1212\/WNL.45.9.1743","article-title":"Response and immunoresistance to botulinum toxin injections","volume":"45","author":"Jankovic","year":"1995","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041008221806200_b12-0720301","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","article-title":"Botulinum toxin in clinical practice","volume":"75","author":"Jankovic","year":"2004","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t2019041008221806200_b13-0720301","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.46.4.1066","article-title":"Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective randomized, double-blind controlled trial","volume":"46","author":"Brans","year":"1996","journal-title":"Neurology"},{"key":"key\n\t\t\t\t2019041008221806200_b14-0720301","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.2165\/00003495-200161130-00004","article-title":"Cervical dystonia pathophysiology and treatment options","volume":"61","author":"Velickovic","year":"2001","journal-title":"Drugs"},{"issue":"1","key":"key\n\t\t\t\t2019041008221806200_b15-0720301","first-page":"CD003633","article-title":"Botulinum toxin type A therapy for cervical dystonia","author":"Costa","year":"2005","journal-title":"Cochrane Database Syst Rev"},{"key":"key\n\t\t\t\t2019041008221806200_b16-0720301","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0031-6997(25)06852-8","article-title":"The origin, structure and pharmacological activity of botulinum toxin","volume":"33","author":"Simpson","year":"1981","journal-title":"Pharmacol Rev"},{"key":"key\n\t\t\t\t2019041008221806200_b17-0720301","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/PL00007848","article-title":"A randomized, double-masked, crossover comparison of the efficacy and safety of botulinum toxin type A produced from the original bulk toxin source and current bulk toxin source for the treatment of cervical dystonia","volume":"249","author":"Naumann","year":"2002","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t2019041008221806200_b18-0720301","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(86)92070-2","article-title":"Double-blind study of botulinum toxin in spasmodic torticollis","volume":"2","author":"Tsui","year":"1986","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041008221806200_b19-0720301","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s00415-012-6510-x","article-title":"Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmacoeconomic value","volume":"259","author":"Zoons","year":"2012","journal-title":"J Neurol"},{"key":"key\n\t\t\t\t2019041008221806200_b20-0720301","first-page":"225","article-title":"Survey of practices employed by neurologists for the definition and management of secondary non-response to botulinum toxin in cervical dystonia","volume":"27","author":"Ferreira","year":"2012","journal-title":"Funct Neurol"},{"key":"key\n\t\t\t\t2019041008221806200_b21-0720301","unstructured":"Ipsen Biopharmaceuticals. Dysport (abobotulinumtoxinA) prescribing information. www.dysport.com\/ps\/PDFs\/Dysport_Patiens_PI_Aug2012.pdf (accessed 2014 Jan 10)."},{"key":"key\n\t\t\t\t2019041008221806200_b22-0720301","unstructured":"Merz Pharmaceuticals. Xeomin (incobotulinumtoxinA) prescribing information. www.xeomin.com\/files\/Xeomin_PI.pdf (accessed 2014 Jan 10)."},{"key":"key\n\t\t\t\t2019041008221806200_b23-0720301","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/mds.20468","article-title":"Retrospective evaluation of the dose of Dysport and BOTOX in the management of cervical dystonia and blepharospasm: the REAL DOSE study","volume":"20","author":"Marchetti","year":"2005","journal-title":"Mov Disord"},{"key":"key\n\t\t\t\t2019041008221806200_b24-0720301","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1136\/jnnp.64.1.13","article-title":"What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport","volume":"64","author":"Poewe","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"key\n\t\t\t\t2019041008221806200_b25-0720301","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jns.2011.05.041","article-title":"Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN, Botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia","volume":"308","author":"Comella","year":"2011","journal-title":"J Neuro Sci"},{"key":"key\n\t\t\t\t2019041008221806200_b26-0720301","unstructured":"Department of Veterans Affairs. Federal supply schedule: drug pharmaceutical prices. www.pbm.va.gov\/drugpharmaceuticalprices.asp (accessed 2013 Oct 1)."},{"key":"key\n\t\t\t\t2019041008221806200_b27-0720301","unstructured":"Centers for Medicare and Medicaid Services. Reimbursement schedule. www.cms.gov\/apps\/physician-fee-schedule\/ (accessed 2013 Sep 15)."},{"key":"key\n\t\t\t\t2019041008221806200_b28-0720301","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modeling for health economic evaluation","author":"Briggs","year":"2006"},{"key":"key\n\t\t\t\t2019041008221806200_b29-0720301","first-page":"32","article-title":"Application of probabilistic sensitivity analysis in DA modeling","volume":"37","author":"Shaw","year":"2002","journal-title":"Formulary"},{"key":"key\n\t\t\t\t2019041008221806200_b30-0720301","first-page":"182","volume-title":"Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine","author":"Petitti","year":"2000","edition":"2nd"},{"key":"key\n\t\t\t\t2019041008221806200_b31-0720301","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/hec.903","article-title":"Cost-effectiveness acceptability curves\u2014facts, fallacies, and frequently asked questions","volume":"13","author":"Fenwick","year":"2004","journal-title":"Health Econ"},{"key":"key\n\t\t\t\t2019041008221806200_b32-0720301","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1192\/bjp.187.2.106","article-title":"A guide to cost-effectiveness acceptability curves","volume":"187","author":"Fenwick","year":"2005","journal-title":"Br J Psychiatry"},{"key":"key\n\t\t\t\t2019041008221806200_b33-0720301","unstructured":"Allergan. 2010Annual report. www.allergan.com\/assets\/pdf\/2010AnnualReport.pdf (accessed 2014 Jan 17)."},{"key":"key\n\t\t\t\t2019041008221806200_b34-0720301","unstructured":"Allergan. 2012Annual report. www.allergan.com\/assets\/pdf\/2012AnnualReport.pdf (accessed 2014 Jan 17)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/72\/4\/301\/28320676\/ajhp0301.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T22:53:41Z","timestamp":1747522421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/72\/4\/301\/5111340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,15]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,2,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140276","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2015,2,15]]},"published":{"date-parts":[[2015,2,15]]}}}